Live Nasdaq Composite: Micron Lifts Market Boat Alongside Mixed Economic Signals
NRIX Q1 2026 Earnings
Reported Apr 8, 2026 at 6:02 AM ET · SEC Source
Q1 26 EPS
$-0.79
MISS 3.32%
Est. $-0.76
Q1 26 Revenue
$6.3M
MISS 56.09%
Est. $14.2M
vs S&P Since Q1 26
+28.0%
BEATING MARKET
NRIX +36.5% vs S&P +8.5%
Market Reaction
Did NRIX Beat Earnings? Q1 2026 Results
Nurix Therapeutics delivered a disappointing fiscal first quarter, missing on both the top and bottom lines as collaboration revenue collapsed 66.1% year-over-year to $6.25 million, well short of the $14.24 million consensus, while its loss per share… Read more Nurix Therapeutics delivered a disappointing fiscal first quarter, missing on both the top and bottom lines as collaboration revenue collapsed 66.1% year-over-year to $6.25 million, well short of the $14.24 million consensus, while its loss per share of $0.79 edged past the $0.76 estimate by 3.32%. The sharp revenue decline was driven primarily by the expiration of the initial research term for certain drug targets under the company's Sanofi collaboration, which had contributed meaningfully to the year-ago period's $18.45 million. Research and development expenses climbed to $84.14 million from $69.66 million as Nurix accelerated enrollment in its Phase 2 DAYBreak CLL-201 pivotal trial and ramped contract manufacturing, widening the net loss to $87.17 million. Despite the headline misses, shares rose roughly 9% in the aftermath, with investors appearing to look past near-term financials toward the planned mid-2026 launch of the global Phase 3 DAYBreak CLL-306 confirmatory trial and a 2026 IND submission targeting autoimmune indications; the company held $540.73 million in cash and equivalents to fund that path.
Key Takeaways
- • Decline in Sanofi collaboration revenue as initial research term for certain drug targets ended
- • Increased R&D spending driven by clinical acceleration of bexobrutideg Phase 2 enrollment and Phase 3 enablement
- • Higher compensation and personnel costs across R&D and G&A functions
NRIX Forward Guidance & Outlook
Nurix plans to initiate the global randomized confirmatory Phase 3 DAYBreak CLL-306 trial by mid-2026 comparing bexobrutideg monotherapy to pirtobrutinib in r/r CLL. The company is targeting a 2026 IND submission for bexobrutideg in inflammatory and autoimmune indications using a new tablet formulation. Updated clinical data from the Phase 1a/1b NX-5948-301 study are expected at medical meetings throughout 2026. Nurix anticipates the achievement of substantial research collaboration milestones throughout the terms of its collaborations with Gilead, Sanofi, and Pfizer.
NRIX YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
NRIX Revenue by Segment
With YoY comparisons, source: SEC Filings
“Nurix entered 2026 focused on implementing a comprehensive registrational program designed to establish bexobrutideg as a potential best-in-class medicine for patients with chronic lymphocytic leukemia.”
— Arthur T. Sands, Q1 2026 Earnings Press Release
NRIX Earnings Trends
NRIX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
NRIX EPS Trend
Earnings per share: estimate vs actual
NRIX Revenue Trend
Quarterly revenue: estimate vs actual
NRIX Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-0.76 | $-0.79 | -3.32% | $6.3M | -56.09% |
| Q4 25 BEAT FY | $-0.92 | $-0.82 | +10.85% | $13.6M | +1.22% |
| FY Full Year | — | $-3.05 | — | $84.0M | — |
| Q3 25 MISS | $-0.85 | $-1.03 | -21.08% | $7.9M | -50.85% |
| Q2 25 BEAT | $-0.74 | $-0.52 | +30.15% | $44.1M | +151.56% |